These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 9393187)

  • 1. FDG PET in head and neck cancer.
    Keyes JW; Watson NE; Williams DW; Greven KM; McGuirt WF
    AJR Am J Roentgenol; 1997 Dec; 169(6):1663-9. PubMed ID: 9393187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic head and neck cancer: role and usefulness of FDG PET in locating occult primary tumors.
    AAssar OS; Fischbein NJ; Caputo GR; Kaplan MJ; Price DC; Singer MI; Dillon WP; Hawkins RA
    Radiology; 1999 Jan; 210(1):177-81. PubMed ID: 9885604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission imaging of head and neck cancer, including thyroid carcinoma.
    Schöder H; Yeung HW
    Semin Nucl Med; 2004 Jul; 34(3):180-97. PubMed ID: 15202100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The role and limitations of FDG-PET in head and neck cancer].
    Horiuchi C; Tsukuda M; Matsuda H; Taguchi T; Nishimura G; Takahashi M; Watanabe M; Komatsu M
    Gan To Kagaku Ryoho; 2009 Dec; 36(13):2542-6. PubMed ID: 20009454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unknown primary detected by FDG-PET. A review of the present indications of FDG-PET in head and neck cancers.
    Sheikholeslam-zadeh R; Choufani G; Goldman S; Hassid S
    Acta Otorhinolaryngol Belg; 2002; 56(1):77-82. PubMed ID: 11894635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer.
    Lindholm P; Leskinen-Kallio S; Minn H; Bergman J; Haaparanta M; Lehikoinen P; Någren K; Ruotsalainen U; Teräs M; Joensuu H
    J Nucl Med; 1993 Oct; 34(10):1711-6. PubMed ID: 8410288
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Utility of combined (18)F-fluorodeoxyglucose-positron emission tomography and computed tomography in patients with cervical metastases from unknown primary tumors.
    Roh JL; Kim JS; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Oral Oncol; 2009 Mar; 45(3):218-24. PubMed ID: 18804404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic evaluation of malignant head and neck cancer by F-18-FDG PET compared to CT/MRI.
    Nowak B; Di Martino E; Jänicke S; Cremerius U; Adam G; Zimny M; Reinartz P; Büll U
    Nuklearmedizin; 1999; 38(8):312-8. PubMed ID: 10615664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of positron emission tomography in occult primary head and neck cancers.
    Safa AA; Tran LM; Rege S; Brown CV; Mandelkern MA; Wang MB; Sadeghi A; Juillard G
    Cancer J Sci Am; 1999; 5(4):214-8. PubMed ID: 10439166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 18F-fluorodeoxyglucose dual-head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer.
    Stokkel MP; Moons KG; ten Broek FW; van Rijk PP; Hordijk GJ
    Cancer; 1999 Dec; 86(11):2370-7. PubMed ID: 10590380
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body (18)F-fluorodeoxyglucose positron emission tomography in patients with head and neck cancer.
    Kitagawa Y; Nishizawa S; Sano K; Sadato N; Maruta Y; Ogasawara T; Nakamura M; Yonekura Y
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2002 Feb; 93(2):202-7. PubMed ID: 11862212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET to evaluate combined intra-arterial chemotherapy and radiotherapy of head and neck neoplasms.
    Kitagawa Y; Sadato N; Azuma H; Ogasawara T; Yoshida M; Ishii Y; Yonekura Y
    J Nucl Med; 1999 Jul; 40(7):1132-7. PubMed ID: 10405132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Surveillance for recurrent head and neck cancer using positron emission tomography.
    Lowe VJ; Boyd JH; Dunphy FR; Kim H; Dunleavy T; Collins BT; Martin D; Stack BC; Hollenbeak C; Fletcher JW
    J Clin Oncol; 2000 Feb; 18(3):651-8. PubMed ID: 10653881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [F-18 FDG PET for detection of occult primary tumor in patients with lymphatic metastases of the neck region].
    Bohuslavizki KH; Klutmann S; Sonnemann U; Thoms J; Kröger S; Werner JA; Mester J; Clausen M
    Laryngorhinootologie; 1999 Aug; 78(8):445-9. PubMed ID: 10488465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status of FDG-PET for head and neck cancer.
    Wong RJ
    J Surg Oncol; 2008 Jun; 97(8):649-52. PubMed ID: 18493944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDG PET detection of unknown primary tumors.
    Bohuslavizki KH; Klutmann S; Kröger S; Sonnemann U; Buchert R; Werner JA; Mester J; Clausen M
    J Nucl Med; 2000 May; 41(5):816-22. PubMed ID: 10809197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical value of 18F-FDG PET-CT in detecting primary tumor for patients with carcinoma of unknown primary.
    Han A; Xue J; Hu M; Zheng J; Wang X
    Cancer Epidemiol; 2012 Oct; 36(5):470-5. PubMed ID: 22504050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Utility of 18F-FDG PET/CT for detecting neck metastasis in patients with salivary gland carcinomas: preoperative planning for necessity and extent of neck dissection.
    Kim MJ; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2013 Mar; 20(3):899-905. PubMed ID: 23161114
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG-PET/CT for detection of the unknown primary head and neck tumor.
    Johansen J; Petersen H; Godballe C; Loft A; Grau C
    Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):500-8. PubMed ID: 22019707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of PET in unknown primary with cervical metastasis: a retrospective study.
    Dandekar MR; Kannan S; Rangarajan V; Purandare NC; Chaukar DA; Deshmukh A; D'cruz AK
    Indian J Cancer; 2011; 48(2):181-6. PubMed ID: 21768663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.